3D Signatures (TSX-V:DXD) has appointed Jason Flowerday as CEO. He succeeds Ferenc Somogyvari, who will remain on the board.
“Mr. Flowerday is a highly respected biotech entrepreneur with more than 20 years of executive life sciences management and startup experience. He has the entrepreneurial and management skills we need to drive us to commercialization,” John Swift, chairman, said in a statement.
“His pharmaceutical background is also ideally suited to pursue new business opportunities in the field of precision medicine and companion diagnostics,” he added.
Mr. Flowerday’s life sciences leadership experience includes over a decade of business development and marketing work for two of the world’s largest pharmaceutical companies, Germany’s Bayer AG and U.S.-based Johnson & Johnson.
“We are committed to changing the way patients are diagnosed and treated and are confident 3D Signatures’ proprietary software platform will be instrumental in improving patient outcomes,” Mr. Flowerday said.